Fecal microbiota transplant – a new frontier in inflammatory bowel disease

Tagore Sunkara,1 Prashanth Rawla,2 Andrew Ofosu,1 Vinaya Gaduputi3 1Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Mount Sinai Health System, New York, NY, USA; 2Department of Internal Medicine, Sovah Health, Martinsville, VA, USA; 3Division of Gastroenterology, SBH Healt...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sunkara T, Rawla P, Ofosu A, Gaduputi V
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
FMT
IBD
Acceso en línea:https://doaj.org/article/dd1fb66cce054d6bba96c62a529e2c04
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:dd1fb66cce054d6bba96c62a529e2c04
record_format dspace
spelling oai:doaj.org-article:dd1fb66cce054d6bba96c62a529e2c042021-12-02T07:03:59ZFecal microbiota transplant – a new frontier in inflammatory bowel disease1178-7031https://doaj.org/article/dd1fb66cce054d6bba96c62a529e2c042018-08-01T00:00:00Zhttps://www.dovepress.com/fecal-microbiota-transplant-a-new-frontier-in-inflammatory-bowel-disea-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Tagore Sunkara,1 Prashanth Rawla,2 Andrew Ofosu,1 Vinaya Gaduputi3 1Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Mount Sinai Health System, New York, NY, USA; 2Department of Internal Medicine, Sovah Health, Martinsville, VA, USA; 3Division of Gastroenterology, SBH Health System, Bronx, NY, USA Abstract: Inflammatory bowel disease (IBD) is a chronic multifactorial disease that affects the gastrointestinal tract and results from an aberrant immune response toward luminal antigens in genetically susceptible people. Most of the current therapies for IBD focus on the management of the inflammation by using corticosteroids, immune modulators, and more recently, monoclonal antibodies (biological therapy). Although these therapies provide benefit in most cases, there are still a significant number of patients who do not respond or become refractory over time, suggesting the need for alternative therapeutic options. In the last decade, it has been recognized that “dysbiosis,” an imbalanced gut microbiota, is a key element in IBD suggesting microbiome-based therapies as an attractive approach. Recently, fecal microbiota transplant (FMT) has been successfully used for the treatment of Clostridium difficile infection, and it is now under investigation for the treatment of IBD. Clinical trials data are still poor but strongly support a future introduction of FMT in therapy to manage IBD microbiome. More studies are needed to assess the optimal route of administration and the frequency of FMT, the best matched donor for each patient as well as the risks associated with FMT in IBD. Keywords: fecal microbiota transplant, FMT, inflammatory bowel disease, IBD, microbiome, dysbiosis, ulcerative colitis, Crohn’s diseaseSunkara TRawla POfosu AGaduputi VDove Medical PressarticleFecal Microbiota TransplantFMTInflammatory bowel diseaseIBDmicrobiomedysbiosisPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 11, Pp 321-328 (2018)
institution DOAJ
collection DOAJ
language EN
topic Fecal Microbiota Transplant
FMT
Inflammatory bowel disease
IBD
microbiome
dysbiosis
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
spellingShingle Fecal Microbiota Transplant
FMT
Inflammatory bowel disease
IBD
microbiome
dysbiosis
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Sunkara T
Rawla P
Ofosu A
Gaduputi V
Fecal microbiota transplant – a new frontier in inflammatory bowel disease
description Tagore Sunkara,1 Prashanth Rawla,2 Andrew Ofosu,1 Vinaya Gaduputi3 1Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Mount Sinai Health System, New York, NY, USA; 2Department of Internal Medicine, Sovah Health, Martinsville, VA, USA; 3Division of Gastroenterology, SBH Health System, Bronx, NY, USA Abstract: Inflammatory bowel disease (IBD) is a chronic multifactorial disease that affects the gastrointestinal tract and results from an aberrant immune response toward luminal antigens in genetically susceptible people. Most of the current therapies for IBD focus on the management of the inflammation by using corticosteroids, immune modulators, and more recently, monoclonal antibodies (biological therapy). Although these therapies provide benefit in most cases, there are still a significant number of patients who do not respond or become refractory over time, suggesting the need for alternative therapeutic options. In the last decade, it has been recognized that “dysbiosis,” an imbalanced gut microbiota, is a key element in IBD suggesting microbiome-based therapies as an attractive approach. Recently, fecal microbiota transplant (FMT) has been successfully used for the treatment of Clostridium difficile infection, and it is now under investigation for the treatment of IBD. Clinical trials data are still poor but strongly support a future introduction of FMT in therapy to manage IBD microbiome. More studies are needed to assess the optimal route of administration and the frequency of FMT, the best matched donor for each patient as well as the risks associated with FMT in IBD. Keywords: fecal microbiota transplant, FMT, inflammatory bowel disease, IBD, microbiome, dysbiosis, ulcerative colitis, Crohn’s disease
format article
author Sunkara T
Rawla P
Ofosu A
Gaduputi V
author_facet Sunkara T
Rawla P
Ofosu A
Gaduputi V
author_sort Sunkara T
title Fecal microbiota transplant – a new frontier in inflammatory bowel disease
title_short Fecal microbiota transplant – a new frontier in inflammatory bowel disease
title_full Fecal microbiota transplant – a new frontier in inflammatory bowel disease
title_fullStr Fecal microbiota transplant – a new frontier in inflammatory bowel disease
title_full_unstemmed Fecal microbiota transplant – a new frontier in inflammatory bowel disease
title_sort fecal microbiota transplant – a new frontier in inflammatory bowel disease
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/dd1fb66cce054d6bba96c62a529e2c04
work_keys_str_mv AT sunkarat fecalmicrobiotatransplantndashanewfrontierininflammatoryboweldisease
AT rawlap fecalmicrobiotatransplantndashanewfrontierininflammatoryboweldisease
AT ofosua fecalmicrobiotatransplantndashanewfrontierininflammatoryboweldisease
AT gaduputiv fecalmicrobiotatransplantndashanewfrontierininflammatoryboweldisease
_version_ 1718399665852907520